Synergistic effect between sphingosine-1-phosphate and chemotherapy drugs against human brainmetastasized breast cancer MDA-MB-361 cells

Journal of Cancer

Volumn 4, Issue 4, 2013, Pages 315-319

  Sultan, Ahlam ^a   Ling, Binbing ^a   Zhang, Huihua ^b   Ma, Baohua ^c   Michel, Deborah ^a   Alcorn, Jane ^a   Yang, Jian ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b FOSHAN UNIVERSITY   (China)

^c Nanhai Entry Exit Inspection and Quarantine Bureau   (China)

Author keywords

Apoptosis; Brain metastasized breast cancer; Chemotherapy; Cytotoxicity; Sphingosine 1 phosphate

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL;

EID: 84882987335     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5956     Document Type: Article

References (21)

1. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381: 800-3.
2. Aoyagi T, Nagahashi M, Yamada A, Takabe K. The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. Lymphat Res Biol. 2012; 10: 97-106.
3. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine- 1-phosphate signaling and its role in disease. Trends Cell Biol. 2012; 22: 50-60.
4. Spiegel S, Milstien S. Sphingosine-1-phosphate: signaling inside and out. FEBS Lett. 2000; 476: 55-7.
5. Johnson KR, Johnson KP, Becker KP, Bielawski J, Mao C, Obeid LM. Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J Biol Chem. 2003; 278: 34541-7.
6. Oskouian B, Mendel J, Shocron E, Lee MA Jr, Fyrst H, Saba JD. Regulation of sphingosine-1-phosphate lyase gene expression by members of the GATA family of transcription factors. J Biol Chem. 2005; 280: 18403-10.
7. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol. 2010; 688: 185-205.
8. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10: 489-503.
9. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta. 2006; 1758: 2016-26.
10. 2+ homoeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts. Biochem J. 2012; 447: 457-64.
11. Davaille J, Li L, Mallat A, Lotersztajn S. Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem. 2002; 277: 37323-30.
12. Hung WC, Chuang LY. Induction of apoptosis by sphingosine- 1-phosphate in human hepatoma cells is associated with enhanced expression of bax gene product. Biochem Biophys Res Commun. 1996; 229: 11-5.
13. Ling B, Chen L, Alcorn J, Ma B, Yang J. Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer. Invest New Drugs. 2011; 29: 396-9.
14. Pinzón-Daza ML, Garzón R, Couraud PO, Romero IA, Weksler B, Ghigo D, Bosia A, Riganti C. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol. 2012; 167: 1431-47.
15. Azim HA, Azim HA Jr. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol. 2012; 8: 135-44.
16. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci USA. 2012; 109: 15930-5.
17. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti- atherogenic mediator? Biochim Biophys Acta. 2002; 1582: 132-7.
18. Watson L, Tullus K, Marks SD, Holt RC, Pilkington C, Beresford MW. Increased serum concentration of sphingosine-1-phosphate in juvenile- onset systemic lupus erythematosus. J Clin Immunol. 2012; 32: 1019-25.
19. Ravell A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol. 2005; 17: 568-73.
20. Perez EA., Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailliard JA, Nair S, Kardinal CG. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000; 88: 124-31.
21. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010; 21: 961-7.